Abstract:Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a common therapy for pediatric hematologic malignancies. With improved supportive care, addressing treatment-related late effects is at the forefront of survivor long-term health and quality of life. We previously demonstrated that alloHSCT survivors had increased adiposity, decreased lean mass, and lower bone density and strength, 7 years (median) from alloHSCT compared to their healthy peers. Yet it is unknown whether these deficits persist. Our longitudinal study characterized changes in muscle and bone over a period of 3.4 (range, 2.0 to 4.9) years in 47 childhood alloHSCT survivors, age 5-26 years at baseline (34% female). Tibia cortical bone geometry and volumetric density and lower leg muscle cross-sectional area (MCSA) were assessed via peripheral quantitative computed tomography (pQCT). Anthropometric and pQCT measurements were converted to age, sex, and ancestry-specific standard deviation scores, adjusted for leg length. Muscle-specific force was assessed as strength relative to MCSA adjusted for leg length (strength Z-score). Measurements were compared to a healthy reference cohort (n = 921), age 5-30 years (52% female). At baseline and follow-up, alloHSCT survivors demonstrated lower height Z-scores, weight Z-scores, and leg length Z-scores compared to the healthy reference cohort. Deficits in MCSA, trabecular volumetric bone density, and cortical bone size and estimated strength (section modulus) were evident in survivors (all p < 0.05). Between the two study time points, anthropometric, muscle, and bone Z-scores did not change significantly in alloHSCT survivors. Approximately 15% and 17% of alloHSCT survivors had MCSA and section modulus Z-score < -2.0, at baseline and follow-up, respectively. Furthermore, those with a history of total body irradiation compared to those without demonstrated lower MCSA at follow-up. The persistent muscle and bone deficits in pediatric alloHSCT survivors support the need for strategies to improve bone and muscle health in this at-risk population. © 2022 American Society for Bone and Mineral Research (ASBMR).

A further case of chondrodysplasia with growth failure occurring after hematopoietic stem cell transplantation (HSCT)

Steroid-responsive anemia with bony dysplasias: What lurks behind!

The late effects of haematopoietic stem cell transplants in paediatric patients: a 25 year review

Persistent Musculoskeletal Deficits in Pediatric, Adolescent and Young Adult Survivors of Allogeneic Hematopoietic Stem‐Cell Transplantation

Bone Marrow Transplantation from an HLA-matched Unrelated Donor for Treatment of Chediak-Higashi Syndrome.

Early skeletal outcomes after hematopoietic stem and progenitor cell gene therapy for Hurler syndrome

Late effects after stem cell transplantation (SCT) in children – growth and hormones

Cleidocranial dysplasia with growth hormone deficiency: a case report

Growth Hormone Therapy in a Boy with X-linked Spondyloepiphyseal Dysplasia Tarda: a 3-Year Observation.

Bone remodeling in survivors of pediatric hematopoietic stem cell transplantation: Impact of heavy resistance training

Achondroplasia current concept of orthopaedic management

A girl with a novel nonsense mutation in Chediak-Higashi syndrome was relieved successfully by treatment with HCST and UCBT: a case report

New treatments for children with achondroplasia

Musculoskeletal Issues in Children and Adolescents: Genetic Musculoskeletal Disorders

Long‐term effects of high‐dose systemic corticosteroids on growth and bone mineral density in patients treated for childhood interstitial lung disease (chILD)

The sequelae of hematopoietic stem cell transplantation in adolescents and young adults: protocol for a systematic review

Polymyositis in a Child with Thalassemia after Hematopoietic Stem Cell Transplantation: A Case Report

The Effects of Surgical Treatment with Chondroblastoma in Children and Adolescents in Open Epiphyseal Plate of Long Bones

Effects of Chemotherapy on Bone Metabolism and Skeletal Growth

Secondary haematological dysplasia after CAR‐T‐cell therapy for acute lymphoblastic leukaemia in children

A Case of Cleidocranial Dysplasia with a Novel Mutation and Growth Velocity Gain with Growth Hormone Treatment